Hormone replacement therapy and hypercoagulability. Results from the Prospective Collaborative Danish Climacteric study

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 110, Issue 6, 2003, Pages 541-547

  Sidelmann, J J ^a,b   Jespersen, J ^a,b   Andersen, L F ^c,d   Skouby, S O ^d,e  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ESBJERG HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d Rigshospitalet   (Denmark)

^e FREDERIKSBERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; BLOOD CLOTTING INHIBITOR; CYPROTERONE ACETATE PLUS ESTRADIOL VALERATE; ESTRADIOL VALERATE PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; ESTROGEN PLUS NORETHINDRONE ACETATE; FIBRIN; FIBRIN DEGRADATION PRODUCT; HORMONE; LEVONORGESTREL; PROTEIN C; PROTEIN S; PROTHROMBIN; UNCLASSIFIED DRUG;

ADULT; ANAMNESIS; ARTICLE; CLIMACTERIUM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DENMARK; DRUG EFFECT; FEMALE; HEALTH STATUS; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; HYPERCOAGULABILITY; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN DETERMINATION; THROMBOEMBOLISM; TIME;

EID: 0037904153     PISSN: 14700328     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-0528.2003.02165.x     Document Type: Article

References (32)

1. Hulley S., Grady D., Bush Tet al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 280:1998;605-613.
2. Grady D., Herrington D., Bittner Vet al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS-II). JAMA. 288:2002;99-101.
3. Jick H., Derby L.E., Myers M.W., Vasilakis C., Newton K.M. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogen. Lancet. 348:1996;981-983.
4. Hulley S., Furberg C., Barrett-Connor Eet al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS-II). JAMA. 288:2002;58-66.
5. Daly E., Vessey M.P., Hawkins M.M., Carson J.L., Gough P., Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 348:1996;977-980.
6. Høibraaten E., Qvigstad E., Arnesen H., Larsen S., Wickstrøm E., Sandset P.M. Increased risk of recurrent venous thromboembolism during hormone replacement therapy. Thromb Haemost. 84:2000;961-967.
7. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 288:2002;321-333.
8. Boshetti C., Cortellaro M., Nencioni T., Bertolli V., Delle Volpe A., Zanussi C. Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women. Thromb Res. 62:1991;1-8.
9. Kroon U-B, Silfverstolpe G., Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost. 71:1994;420-423.
10. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study. Thromb Haemost. 75:1996;476-480.
11. Caine Y.G., Bauer K., Barzegar Set al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost. 68:1992;392-395.
12. Høibraaten E., Os I., Seljeflot I., Andersen T.O., Hofstad A-E, Sandset P.M. The effects of hormone replacement therapy on haemostatic variables in women with angiographically verified coronary artery disease: results from the Estrogen in Women with Atherosclerosis Study. Thromb Res. 98:2000;19-27.
13. van Baal W.M., Emeis J.J., van der Mooren M.J., Kessel H., Kenemans P., Stehouwer C.D.A. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study. Thromb Haemost. 83:2000;29-34.
14. Scarabin P-Y, Alhenc-Gelas M., Plu-Bureau G., Taisne P., Agher R., Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol. 17:1997;3071-3078.
15. De Mitrio V., Marino R., Cicinelli Eet al. Beneficial effects of postmenopausal hormone replacement therapy with transdermal estradiol on sensitivity to activated protein C. Blood Coagulation Fibrinolysis. 11:2000;175-182.
16. Douketis J.D., Gordon M., Johnston M., Julian J.A., Adachi J.R., Ginsberg J.S. The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: prospective cohort study and review of the literature. Thromb Res. 99:2000;25-34.
17. Høibraaten E., Mowinckel M-C, De Ronde H., Bertina R.M., Sandset P.M. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol. 115:2001;415-420.
18. Jespersen J., Bertina R.M., Haverkate F. Laboratory Techniques in Thrombosis. A Manual. Second Revised Edition of ECAT Assay Procedures. 1999;1-308 Kluwer Academic Publishers, Dordrecht.
19. Skouby S.O., Gram J., Andersen L.F., Sidelmann J., Petersen K.R., Jespersen J. Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein. Am J Obstet Gynecol. 186:2002;969-977.
20. Matthews J.N., Altman D.G., Campbell M.J., Royston P. Analysis of serial measurements in medical research. BMJ. 300:1990;230-235.
21. Høibraaten E., Qvigstad E., Andersen T.O., Mowinckel M-C, Sandset P.M. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism - results from a randomized, double-blind, clinical trial. Thromb Haemost. 185:2001;775-781.
22. Gottsäter A., Rendell M., Hulthen U.L., Berntorp E., Mattiason I. Hormone replacement therapy in healthy postmenopausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolytic factors. J Intern Med. 249:2001;237-246.
23. Kessler C.M., Szymanski L.M., Shamsipour Z., Muesing R.A., Miller V.T., Larosa J.C. Estrogen replacement therapy and coagulation: relationship to lipid and lipoprotein changes. Obstet Gynecol. 89:1997;326-331.
24. van de Poel R.H., Meijers J.C., Bouma B.N. C4b-binding protein inhibits the factor V-dependent but not the factor V-independent cofactor activity of protein S in the activated protein C-mediated inactivation of factor VIIIa. Thromb Haemost. 85:2001;761-765.
25. Cushmann M., Meilahn E.N., Psaty B.M., Kuller L.H., Dobs A.S., Tracy R.P. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol. 19:1999;893-899.
26. van Wersch J.W.J., Ubachs J.M.H., van den Ende A., van Enk A. The effect of two regimens of hormone replacement therapy on the haemostatic profile in postmenopausal women. Eur J Clin Chem Clin Biochem. 32:1994;449-453.
27. Teede H.J., McGrath B.P., Smolich JJet al. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol. 20:2000;1404-1409.
28. Koh K.K., Mincemoyer R., Minh NBet al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med. 336:1997;683-690.
29. Miller J., Chan B.K., Nelson H.D. Postmenopausal estrogen replacement and the risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Task Force. Ann Intern Med. 136:2002;680-690.
30. Herrington D.M., Vittinghoff E., Howard TDet al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol. 22:2002;1012-1017.
31. Rosendaal F.R., Vessey M., Rumley Aet al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol. 116:2002;851-854.
32. Lowe G., Woodward M., Vessey M., Rumley A., Gough P., Daly E. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy. Thromb Haemost. 83:2000;530-535.